

LATEST NEWS

**PRESS RELEASE**

**A Multimodal Approach for Novel Insights on Lung Cancer**

*"Unlocking the synergistic potential of multimodal health data through artificial intelligence holds revolutionary promise for the future of personalized medicine."*  
Dr. Philippe Menu, Chief Medical Officer

**SOPHiA GENETICS teams up with the Spanish Lung Cancer Group**

Earlier this month, we announced a clinical research partnership initiative with the Spanish Lung Cancer Group to apply our radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemioimmunotherapy in resectable stage IIIA non-small cell lung cancer (NSCLC).

"Unlocking the synergistic potential of multimodal health data through artificial intelligence holds revolutionary promise for the future of personalized medicine in oncology and many other health conditions," said Dr. Philippe Menu, our Chief Medical Officer.

[read the press release](#)

PRESS HIGHLIGHT

**Precision Oncology News**

SOPHiA GENETICS, Spanish Lung Cancer Group Team Up to Predict Lung Cancer Treatment Response

08 FEB 2021



NEXT EVENT

**AGBT**  
01 - 03 MAR 2021  
Virtual meeting



**Tracking COVID-19 with a System Clinical Approach**

PMWC COVID-19 LIVE  
JAN 25-27  
PRECISION MEDICINE WORLD CONFERENCE 2021

**A look back at PMWC: COVID-19 Edition**

On January 25th, our Co-Founder Lars Steinmetz was speaking at Precision Medicine World Conference (PMWC) Virtual COVID-19 Edition in an exclusive panel discussion chaired by Lee Hood.

You missed it? You can now watch the replay and discover how our technology can be used to analyze new concerning variants and track where they are populating for pandemic monitoring and management purposes.

[watch the replay](#)

**What you're not seeing can make a difference**

**A robust and accurate assessment of CNVs: why does it matter?**

An accurate assessment of structural variations such as Copy-Number Variants (CNVs) is essential to understand the cause of genetic disorders, but their detection from NGS data can be challenging due to issues intrinsic to the technology. Here is what we offer:

- Technology backed by half a million genomic analyses on targeted panels and exomes
- Solutions tailored for each and every manufacturer and sequencing method
- A dedicated team of experts to support you all along the NGS workflow

With the SOPHiA DDM Platform, you can achieve a highly accurate CNV assessment in a unique workflow.

[read more](#)

**Meet Kathy Hibbs and Ross Muken**

**Introducing our new Board and Executive team members**

This month, two prominent figures joined SOPHiA GENETICS.

First, **Kathy L. Hibbs** was nominated to the Board of Directors and its Audit Committee. Currently holding the position of Chief Legal and Regulatory Officer at 23andMe, Kathy is regularly recognized as one of the Bay Area's most influential women by both the San Francisco and Silicon Valley Business Journals.

On the Executive team side, **Ross Muken** was appointed Chief Financial Officer (CFO). He brings more than 20 years of financial leadership experience with a strong focus on the medical technology and life sciences space.

[read the press releases](#)

UPCOMING EVENTS

	<b>SCOPE</b> 02 - 04 MAR 2021 Virtual meeting	<a href="#">more info</a>
	<b>ECR</b> 03 - 07 MAR 2021 Virtual meeting	<a href="#">more info</a>

**EMPLOYEE MOTIVATION**

*"I was drawn to SOPHiA GENETICS, because of the quality of its team, and the potential the SOPHiA DDM Platform has in integrating insights to serve all oncology stakeholders. I've dedicated my career to improving the outcomes for cancer patients, I see a tremendous opportunity to accelerate this process by leveraging digital innovation, and that's exactly what we do on a daily basis here at SOPHiA GENETICS."*

- Marián Novák,  
Clinical Application Product Manager

**Meet Marián and join the team!**

Inspired by Marián and looking to learn and grow in your next role?

Become a part of the amazing SOPHiA GENETICS journey! Check out our open opportunities.

[see open jobs and apply now](#)

**IN THE PRESS**

	<b>GenomeWeb</b> SOPHiA GENETICS: Kathy Hibbs 19 JAN 2021
	<b>Handelszeitung</b> Trotz Covid-Ängsten: Die Startup-Finanzierung war 2020 robust 29 JAN 2021
	<b>Sud Ouest</b> COVID-19: "Ce virus est mondial, sa surveillance doit l'être aussi" 01 FEB 2021
	<b>BioSpace</b> SOPHiA GENETICS Appoints Ross Muken as Chief Financial Officer 11 FEB 2021

DISCLAIMER

SOPHiA GENETICS products are for Research Use Only (RUO) and not for use in diagnosis. The information included has been prepared for and is intended for viewing by a global audience. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult local sales representatives.